Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

18.42
+0.87004.96%
Post-market: 18.640.2200+1.19%19:50 EDT
Volume:7.07M
Turnover:130.69M
Market Cap:14.69B
PE:-16.48
High:18.83
Open:18.07
Low:17.97
Close:17.55
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:1.28
T/O Rate:4.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:23.33
PE(LYR):-12.76

Loading ...

Arcus Biosciences, Summit Therapeutics Team up to Test Casdatifan-ivonescimab Combo in Kidney Cancer

Reuters
·
Jul 23

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

THOMSON REUTERS
·
Jul 23

Summit Gains on Updated Trial Data for Experimental Lung Cancer Drug

Reuters
·
Jul 22

Summit Therapeutics Announces Availability of Ivonescimab Harmoni Trial Update Press Release

Reuters
·
Jul 22

Summit Therapeutics - FDA Accepts Bla for Ivonescimab; Pdufa Date November 14, 2026

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Phase Iii Harmoni Study Shows Statistically Significant Pfs Benefit

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Ivonescimab Continues to Show Acceptable Safety Profile; no New Safety Signals

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Ivonescimab Plus Chemotherapy Shows Positive Os Trend in Asian and Western Patients

THOMSON REUTERS
·
Jul 22

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase Iii Harmoni Study

THOMSON REUTERS
·
Jul 22

Analysts Are Bullish on These Healthcare Stocks: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT)

TIPRANKS
·
Jul 22

What Comes After Merck's Keytruda? the Race for the Next Standard Cancer Treatment.

Dow Jones
·
Jul 20

Earning Preview: Summit Therapeutics PLC this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Earnings Agent
·
Jul 17

Kalshi to Allow Bets on Clinical Trials, FDA Decisions

Reuters
·
Jul 16

Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

Dow Jones
·
Jul 16

Summit Therapeutics Schedules Q2 2026 Results, Operational Update Call

Reuters
·
Jul 16

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal

Simply Wall St.
·
Jul 15

Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil

MT Newswires Live
·
Jul 14

Summit Therapeutics Signs Agreement to Sell Phase Iii Asset Ridinilazole to Biossil, Inc.

THOMSON REUTERS
·
Jul 14

Summit Therapeutics - to Receive $500,000 Upfront and up to $104.5 Mln in Milestones Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?

Simply Wall St.
·
Jun 25